Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Enzymatic Hydrolysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN104178469B reveals high-purity enzymatic route for Cilastatin intermediate. Offers significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN116622672A reveals high-efficiency carboxylesterase mutants for chiral acid production, offering cost reduction and supply reliability for pharmaceutical intermediates.
Patent CN114957030B reveals Rhodococcus erythropolis AJ270 catalyzed hydrolysis for high-purity chiral intermediates, offering cost reduction and supply chain reliability.
Patent CN105461606B details enzymatic hydrolysis for Ledipasvir intermediates. Achieve >99% de value and cost reduction in pharmaceutical intermediate manufacturing.
Advanced enzymatic hydrolysis method for Ledipasvir intermediate CN105461606B. Ensures high purity and supply chain reliability for pharmaceutical manufacturing partners globally.
Novel enzymatic process for high-purity cefoperazone impurity A ensures reliable supply chain and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN104045655B reveals cost-effective AVNA synthesis. Enhances supply chain reliability and reduces manufacturing costs for cephalosporin intermediates.
Patent CN112359036B discloses engineered nitrilase mutants for efficient synthesis of pregabalin chiral intermediates, offering significant cost reduction in API manufacturing.
Patent CN107988307A details enzymatic resolution for high-purity intermediates. This method offers significant supply chain reliability and cost reduction in pharmaceutical manufacturing.
Patent CN102153566A details a mild enzymatic route for Cefdinir, offering high purity and cost reduction in pharmaceutical manufacturing compared to harsh chemical hydrolysis.
Patent CN114394892B reveals a high-purity synthesis route for R-3-hydroxybutyrate. This method ensures supply chain stability and significant cost reduction.
Patent CN105461606A reveals enzymatic hydrolysis for Ledipasvir intermediates. Achieve >99% de purity and scalable green manufacturing for Hepatitis C drug supply chains.
Patent CN1115343C details a novel enzymatic route for chiral cyclopentene amines, offering cost-effective API intermediate manufacturing with high enantiomeric purity.
Patent CN116121310A reveals a high-efficiency enzymatic route for dexketoprofen, offering superior purity and scalable production for reliable pharmaceutical intermediates suppliers.